新型黏膜保护剂聚普瑞锌临床应用专家共识

Expert Consensus on Clinical Application of A Novel Mucosal Protective Agent-Polaprezinc

胃黏膜损伤的类型和修复结局是备受关注的临床热点问题。以促进胃黏膜结构和功能修复为主要治疗目的,或兼有对抗黏膜表面损伤因子、改善黏膜防御机制作用的药物统称为胃黏膜保护剂。聚普瑞锌作为新一代黏膜保护剂,在化学成分、药代动力学、作用机制等方面与其他同类药物存在明显差异,在临床使用的适应证、潜在不良反应等方面亦有其独特性。该药在中国内地地区新近准入,在临床合理应用方面尚缺乏我国专家共识意见。中华消化心身联盟组织国内关注消化道黏膜修复临床问题的有关专家,基于国内外研究进展和临床应用经验,就应用黏膜保护剂的必要性、胃黏膜保护剂的个体化选择应用要点,以及聚普瑞锌的药代动力学特点、作用机制和临床应用达成共识意见,为聚普瑞锌在消化道黏膜保护中的合理应用提供参考依据。

Gastric mucosal injury and its healing outcome are hot clinical issues.Gastric mucosal protective agent is a kind of drugs which can promote the repair of gastric mucosal structure and function,or can resist the mucosal surface damage factors,and improve the defense mechanism of gastric mucosa.As a new generation of mucosal protective agent,polaprezinc is significantly different from other similar medicines in chemical composition,pharmacokinetics and mechanisms of action,as well as indications and potential adverse reactions.Due to its new access in China′s mainland,there is still lack of consensus among Chinese experts on its rational clinical application.The Chinese Digestive Psychosomatic Union organized experts to reach a consensus on the necessity of the use of mucosal protective agents,the principles for the individualized selection of gastric protective agents,and the pharmacokinetics,mechanisms and clinical application of polaprezinc on the basis of systematic review of research progress and clinical experience.The consensus provides a significant reference for the rational use of polaprezinc in gastrointestinal mucosal protection.